Menu Search

Company Announcements

Dr Martens PLC

Transaction in Own Shares

Source: RNS
RNS Number : 0574X
Dr. Martens PLC
15 December 2023
 


                                                                                                          

DR. MARTENS PLC

 

TRANSACTIONS IN OWN SECURITIES & CONCLUSION OF BUYBACK

 

 

 

Dr. Martens plc ("Dr. Martens") announces today that it has purchased the following number of its ordinary shares of 1 pence each on the London Stock Exchange and Multilateral Trading Facilities from Morgan Stanley & Co. International plc ("Morgan Stanley"). Such purchase forms part of the Company's existing share buyback programme and was effected pursuant to the instructions issued by the Company on 1 June 2023, as announced on 14 July 2023:

 

 

Ordinary Shares

 

Date of purchase:

15 December 2023

Number of ordinary shares purchased:

186,202

Highest price paid per share:

95.05p

Lowest price paid per share:             

93.65p

Volume weighted average price paid per share:

94.63p

 

 

Dr. Martens intends to cancel the purchased shares.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), a full breakdown of the individual trades made by Morgan Stanley on behalf of the Company as part of the share buyback programme is set out in the Schedule to this announcement available through the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/0574X_1-2023-12-15.pdf

 

These purchases are the last purchases to be made under the programme between Dr. Martens, on the one hand, and Morgan Stanley & Co. International plc, on the other hand, announced on 14 July 2023, as that irrevocable programme has been completed.

 

For further information please contact:

 

Paul Rolling

Assistant Company Secretary

+447584 243562

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSTABPTMTBBBPJ